Newron Pharmaceuticals S.p.A. (NP5.DE)
EUR 8.8
(-0.34%)
EUR 8.8
(-0.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.05 Million EUR | 55.38% |
| 2022 | 6.09 Million EUR | 5.76% |
| 2021 | 5.76 Million EUR | 9.59% |
| 2020 | 5.25 Million EUR | -25.29% |
| 2019 | 7.03 Million EUR | 74.86% |
| 2018 | 4.02 Million EUR | -70.03% |
| 2017 | 13.42 Million EUR | 99.64% |
| 2016 | 6.72 Million EUR | 182.61% |
| 2015 | 2.38 Million EUR | 52.86% |
| 2014 | 1.55 Million EUR | -56.0% |
| 2013 | 3.53 Million EUR | -60.34% |
| 2012 | 8.92 Million EUR | 3087.14% |
| 2011 | 280 Thousand EUR | -65.26% |
| 2010 | 806 Thousand EUR | -68.29% |
| 2009 | 2.54 Million EUR | -35.37% |
| 2008 | 3.93 Million EUR | -2.26% |
| 2007 | 4.02 Million EUR | 237.87% |
| 2006 | 1.19 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.4 Million EUR | 0.0% |
| 2023 Q2 | 5.54 Million EUR | 0.0% |
| 2023 Q4 | 3.56 Million EUR | 0.0% |
| 2023 FY | 9.46 Million EUR | 55.38% |
| 2022 Q4 | 3.22 Million EUR | 0.0% |
| 2022 Q2 | 2.91 Million EUR | 0.0% |
| 2022 FY | 6.09 Million EUR | 5.76% |
| 2021 Q4 | 3.18 Million EUR | 0.0% |
| 2021 FY | 5.76 Million EUR | 9.59% |
| 2021 Q2 | 2.66 Million EUR | 0.0% |
| 2020 FY | 5.25 Million EUR | -25.29% |
| 2020 Q4 | 2.73 Million EUR | 0.0% |
| 2020 Q2 | 2.5 Million EUR | 0.0% |
| 2019 Q2 | 2.27 Million EUR | 29.02% |
| 2019 Q1 | 1.75 Million EUR | -12.77% |
| 2019 FY | 7.03 Million EUR | 74.86% |
| 2019 Q4 | 4.84 Million EUR | 0.0% |
| 2018 Q1 | 1 Million EUR | -42.2% |
| 2018 FY | 4.02 Million EUR | -70.03% |
| 2018 Q4 | 2.01 Million EUR | 0.0% |
| 2018 Q2 | 2 Million EUR | 99.55% |
| 2017 Q1 | 3.35 Million EUR | 19.13% |
| 2017 FY | 13.42 Million EUR | 99.64% |
| 2017 Q4 | 1.74 Million EUR | 0.0% |
| 2017 Q2 | 11.68 Million EUR | 248.14% |
| 2016 Q1 | 1.68 Million EUR | 319.33% |
| 2016 Q2 | 3.9 Million EUR | 132.41% |
| 2016 FY | 6.72 Million EUR | 182.61% |
| 2016 Q4 | 2.81 Million EUR | 0.0% |
| 2015 Q1 | 595 Thousand EUR | 278.98% |
| 2015 Q2 | 1.97 Million EUR | 232.61% |
| 2015 Q4 | 401 Thousand EUR | -32.61% |
| 2015 Q3 | 595 Thousand EUR | -69.93% |
| 2015 FY | 2.38 Million EUR | 52.86% |
| 2014 Q4 | 157 Thousand EUR | -59.67% |
| 2014 FY | 1.55 Million EUR | -56.0% |
| 2014 Q2 | 1.4 Million EUR | 259.67% |
| 2014 Q1 | 389.25 Thousand EUR | -71.94% |
| 2014 Q3 | 389.25 Thousand EUR | -72.2% |
| 2013 Q3 | 884.75 Thousand EUR | -58.89% |
| 2013 Q4 | 1.38 Million EUR | 56.77% |
| 2013 Q2 | 2.15 Million EUR | 143.23% |
| 2013 FY | 3.53 Million EUR | -60.34% |
| 2013 Q1 | 884.75 Thousand EUR | 0.0% |
| 2012 Q1 | 2.23 Million EUR | 0.0% |
| 2012 FY | 8.92 Million EUR | 3087.14% |
| 2012 Q4 | 884.75 Thousand EUR | -60.34% |
| 2012 Q3 | 2.23 Million EUR | 0.0% |
| 2012 Q2 | 2.23 Million EUR | 0.0% |
| 2011 Q2 | 70 Thousand EUR | 0.0% |
| 2011 Q4 | 2.23 Million EUR | 3087.14% |
| 2011 FY | 280 Thousand EUR | -65.26% |
| 2011 Q1 | 70 Thousand EUR | 0.0% |
| 2011 Q3 | 70 Thousand EUR | 0.0% |
| 2010 Q3 | 201.5 Thousand EUR | 0.0% |
| 2010 Q4 | 70 Thousand EUR | -65.26% |
| 2010 FY | 806 Thousand EUR | -68.29% |
| 2010 Q1 | 201.5 Thousand EUR | 0.0% |
| 2010 Q2 | 201.5 Thousand EUR | 0.0% |
| 2009 Q4 | 201.5 Thousand EUR | -68.29% |
| 2009 FY | 2.54 Million EUR | -35.37% |
| 2009 Q3 | 635.5 Thousand EUR | 0.0% |
| 2009 Q2 | 635.5 Thousand EUR | 0.0% |
| 2009 Q1 | 635.5 Thousand EUR | 0.0% |
| 2008 Q1 | 983.25 Thousand EUR | 0.0% |
| 2008 Q4 | 635.5 Thousand EUR | -35.37% |
| 2008 FY | 3.93 Million EUR | -2.26% |
| 2008 Q2 | 983.25 Thousand EUR | 0.0% |
| 2008 Q3 | 983.25 Thousand EUR | 0.0% |
| 2007 FY | 4.02 Million EUR | 237.87% |
| 2007 Q4 | 983.25 Thousand EUR | -2.26% |
| 2007 Q3 | 1 Million EUR | 0.0% |
| 2007 Q2 | 1 Million EUR | 0.0% |
| 2007 Q1 | 1 Million EUR | 0.0% |
| 2006 Q2 | 297.75 Thousand EUR | 0.0% |
| 2006 FY | 1.19 Million EUR | 0.0% |
| 2006 Q3 | 297.75 Thousand EUR | 0.0% |
| 2006 Q1 | 297.75 Thousand EUR | 0.0% |
| 2006 Q4 | 1 Million EUR | 237.87% |
| 2005 FY | - EUR | 0.0% |
| 2005 Q1 | - EUR | 0.0% |
| 2005 Q2 | - EUR | 0.0% |
| 2005 Q3 | - EUR | 0.0% |
| 2005 Q4 | 297.75 Thousand EUR | 0.0% |
| 2004 Q4 | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Redcare Pharmacy NV | 1.79 Billion EUR | 99.496% |